Precision Dosing: Public Health Need, Proposed Framework, and Anticipated Impact

Daniel Gonzalez; Gauri G. Rao; Stacy C. Bailey; Kim L.R. Brouwer; Yanguang Cao; Daniel J. Crona; Angela D.M. Kashuba; Craig R. Lee; Kathryn Morbitzer; J. Herbert Patterson; Tim Wiltshire; Jon Easter; Scott W. Savage; J. Robert Powell

doi:10.1111/cts.12490

Precision Dosing: Public Health Need, Proposed Framework, and Anticipated Impact

Daniel Gonzalez^*, Gauri G. Rao, Stacy C. Bailey, Kim L.R. Brouwer, Yanguang Cao, Daniel J. Crona, Angela D.M. Kashuba, Craig R. Lee, Kathryn Morbitzer, J. Herbert Patterson, Tim Wiltshire, Jon Easter, Scott W. Savage, J. Robert Powell

^*Corresponding author for this work

Medicine, General Medicine Division

Research output: Contribution to journal › Review article › peer-review

25 Scopus citations

Original language	English (US)
Pages (from-to)	443-454
Number of pages	12
Journal	Clinical and Translational Science
Volume	10
Issue number	6
DOIs	https://doi.org/10.1111/cts.12490
State	Published - Nov 2017

ASJC Scopus subject areas

Neuroscience(all)
Biochemistry, Genetics and Molecular Biology(all)
Pharmacology, Toxicology and Pharmaceutics(all)

Access to Document

10.1111/cts.12490

Cite this

Gonzalez, D., Rao, G. G., Bailey, S. C., Brouwer, K. L. R., Cao, Y., Crona, D. J., Kashuba, A. D. M., Lee, C. R., Morbitzer, K., Patterson, J. H., Wiltshire, T., Easter, J., Savage, S. W., & Powell, J. R. (2017). Precision Dosing: Public Health Need, Proposed Framework, and Anticipated Impact. Clinical and Translational Science, 10(6), 443-454. https://doi.org/10.1111/cts.12490

Gonzalez, Daniel ; Rao, Gauri G. ; Bailey, Stacy C. ; Brouwer, Kim L.R. ; Cao, Yanguang ; Crona, Daniel J. ; Kashuba, Angela D.M. ; Lee, Craig R. ; Morbitzer, Kathryn ; Patterson, J. Herbert ; Wiltshire, Tim ; Easter, Jon ; Savage, Scott W. ; Powell, J. Robert. / Precision Dosing : Public Health Need, Proposed Framework, and Anticipated Impact. In: Clinical and Translational Science. 2017 ; Vol. 10, No. 6. pp. 443-454.

@article{ce8e73768d274fe8972ee4f75810eee4,

title = "Precision Dosing: Public Health Need, Proposed Framework, and Anticipated Impact",

author = "Daniel Gonzalez and Rao, {Gauri G.} and Bailey, {Stacy C.} and Brouwer, {Kim L.R.} and Yanguang Cao and Crona, {Daniel J.} and Kashuba, {Angela D.M.} and Lee, {Craig R.} and Kathryn Morbitzer and Patterson, {J. Herbert} and Tim Wiltshire and Jon Easter and Savage, {Scott W.} and Powell, {J. Robert}",

note = "Funding Information: research from the National Institute of Child Health and Human Development (K23HD083465), the nonprofit organization Thrasher Research Fund (www.thrasherresearch.org), and from industry (Cempra, Inc. and Jacobus Pharmaceutical Company, Inc.) for drug development in adults and children. S.C.B. has served as a consultant to Merck, Sharp and Dohme and to Luto (UK). She has received funding via her institution from Merck, Sharp and Dohme, Eli Lilly Company, AHRQ, and the National Institutes of Health for studies that use the electronic health record to improve prescribing and patient monitoring. Y.C. recieves support from the National Institute of General Medical Sciences (GM119661). K.L.R.B. receives support from the National Institute of General Medical Sciences through award numbers R01GM041935 and R35GM122576, and from industry (Otsuka Pharmaceutical Development and Commercialization, Inc., and Intercept Pharmaceuticals). K.L.R.B. is a coinventor of the sandwich-cultured hepatocyte technology for quantification of biliary excretion (B-CLEAR) and related technologies, which have been licensed exclusively to Qualyst Transporter Solutions, LLC. A.D.M.K. receives support for research from the National Institute of Allergy and Infectious Diseases (R01AI122319, R01AI111891, P30AI050410, R01AI116276, R01AI117739, U01AI103390, UM1AI126619), the National Center for Advancing Translational Sciences (UL1TR001111), the National Institute of Child Health and Human Development (K12HD001441), and from industry (Gilead, Merck) for clinical pharmacology and drug development. C.R.L. receives research support from the American Heart Association (16GRNT29300003). J.R.P. has served as paid consultant to Takeda, AbbVie, and Hengrui Pharmaceuticals over the past year. The remaining authors have no conflicts to disclose. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.",

year = "2017",

month = nov,

doi = "10.1111/cts.12490",

language = "English (US)",

volume = "10",

pages = "443--454",

journal = "Clinical and Translational Science",

issn = "1752-8054",

publisher = "Wiley-Blackwell",

number = "6",

}

Precision Dosing : Public Health Need, Proposed Framework, and Anticipated Impact. / Gonzalez, Daniel; Rao, Gauri G.; Bailey, Stacy C.; Brouwer, Kim L.R.; Cao, Yanguang; Crona, Daniel J.; Kashuba, Angela D.M.; Lee, Craig R.; Morbitzer, Kathryn; Patterson, J. Herbert; Wiltshire, Tim; Easter, Jon; Savage, Scott W.; Powell, J. Robert.

In: Clinical and Translational Science, Vol. 10, No. 6, 11.2017, p. 443-454.

Research output: Contribution to journal › Review article › peer-review

TY - JOUR

T1 - Precision Dosing

T2 - Public Health Need, Proposed Framework, and Anticipated Impact

AU - Gonzalez, Daniel

AU - Rao, Gauri G.

AU - Bailey, Stacy C.

AU - Brouwer, Kim L.R.

AU - Cao, Yanguang

AU - Crona, Daniel J.

AU - Kashuba, Angela D.M.

AU - Lee, Craig R.

AU - Morbitzer, Kathryn

AU - Patterson, J. Herbert

AU - Wiltshire, Tim

AU - Easter, Jon

AU - Savage, Scott W.

AU - Powell, J. Robert

N1 - Funding Information: research from the National Institute of Child Health and Human Development (K23HD083465), the nonprofit organization Thrasher Research Fund (www.thrasherresearch.org), and from industry (Cempra, Inc. and Jacobus Pharmaceutical Company, Inc.) for drug development in adults and children. S.C.B. has served as a consultant to Merck, Sharp and Dohme and to Luto (UK). She has received funding via her institution from Merck, Sharp and Dohme, Eli Lilly Company, AHRQ, and the National Institutes of Health for studies that use the electronic health record to improve prescribing and patient monitoring. Y.C. recieves support from the National Institute of General Medical Sciences (GM119661). K.L.R.B. receives support from the National Institute of General Medical Sciences through award numbers R01GM041935 and R35GM122576, and from industry (Otsuka Pharmaceutical Development and Commercialization, Inc., and Intercept Pharmaceuticals). K.L.R.B. is a coinventor of the sandwich-cultured hepatocyte technology for quantification of biliary excretion (B-CLEAR) and related technologies, which have been licensed exclusively to Qualyst Transporter Solutions, LLC. A.D.M.K. receives support for research from the National Institute of Allergy and Infectious Diseases (R01AI122319, R01AI111891, P30AI050410, R01AI116276, R01AI117739, U01AI103390, UM1AI126619), the National Center for Advancing Translational Sciences (UL1TR001111), the National Institute of Child Health and Human Development (K12HD001441), and from industry (Gilead, Merck) for clinical pharmacology and drug development. C.R.L. receives research support from the American Heart Association (16GRNT29300003). J.R.P. has served as paid consultant to Takeda, AbbVie, and Hengrui Pharmaceuticals over the past year. The remaining authors have no conflicts to disclose. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

PY - 2017/11

Y1 - 2017/11

UR - http://www.scopus.com/inward/record.url?scp=85032922602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032922602&partnerID=8YFLogxK

U2 - 10.1111/cts.12490

DO - 10.1111/cts.12490

M3 - Review article

C2 - 28875519

AN - SCOPUS:85032922602

VL - 10

SP - 443

EP - 454

JO - Clinical and Translational Science

JF - Clinical and Translational Science

SN - 1752-8054

IS - 6

ER -